


# **Opening Remark**


#### 2021.06.02





### A revolutionary change in early clinical designs


#### Phase IB or Phase II



https://www.annalsofoncology.org/article/S0923-7534(19)45984-X/fulltext



#### Precision Designs: Basket and Umbrella Designs



https://www.annalsofoncology.org/article/S0923-7534(19)45984-X/fulltext





- 1. Defining the right patient population
- 2. Describing the NME pharmacokinetic characteristics
- 3. Determining the NME PD biomarkers such as target engagement, key pathway modulation and biological effect
- 4. Discovering intermediate biomarkers of response
- 5. Assess tumor response at the end of treatment
- 6. Learning how to overcome tumor resistance paradigms



### P1 for Seamless designs



- Higher doses of may not induce a higher immunological effects because of plateau.
- AEs are typically non-dose related and their time frame can prolong itself.
- The goal is to locate OBD (Optimal Biological/Immunological Dose), not MTD.

	Historical Designs	Seamless Designs
Recommended D.	MTD	OID
Study Goals	DLT Dose-finding studies	TLT Dose-ranging studies
AEs	Dose related	Non-dose related
Study size	Small	Can be large



#### **Types of Cancer Treatment**



- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotheraphy
- Targeted Therapy
- Hormone Therapy
- Stem Cell Transplant
- Biomarker Testing for Cancer Treatment



#### **Route of Administration**



- Oral
- Intravenous (IV)
- Injection
- Intrathecal
- Intraperitoneal (IP)
- Intra-arterial (IA)
- Topical



### **Types of immunotherapy**



- Immune checkpoint inhibitors
- T-cell transfer therapy
- Monoclonal antibodies
- Treatment vaccines
- Immune system modulators



#### **Targeted Therapy**



- Small-molecule drugs
- Monoclonal antibodies







• Hormone therapy falls into two broad groups, those that block the body's ability to produce hormones and those that interfere with how hormones behave in the body.



#### **Stem Cell Therapy**



- Autologous, which means the stem cells come from the patient
- Allogeneic, which means the stem cells come from someone else. The donor may be a blood relative but can also be someone who is not related.
- Syngeneic, which means the stem cells come from the identical twin, if there is one.



- Biomarker tests can help you and your doctor select a cancer treatment for you. Some cancer treatments, including <u>targeted</u> <u>therapies</u> and <u>immunotherapies</u>, may only work for people whose cancers have certain biomarkers.
- For example, people with cancer that has certain genetic changes in the *EGFR* gene can get treatments that targets those changes, called <u>EGFR inhibitor</u>. In this case, biomarker testing can find out whether someone's cancer has an EGFR gene change that can be treated with an EGFR inhibitor.



- Biomarker test는 항암치료 선택에 보조수단으로 쓰인다. 대부분 biomarker는 genetic marker와 관계되어 있지만 biomarker에 따라서 protein 또는 다른 marker를 찾는데 응용된다.
- Biomarker에 따라서 한가지 biomarker를 하거나 여러 biomarker를 동시에 test 하기도 하는데 <u>multigene test</u>s 또는 panel tests라고 한다. 예를 들어 <u>Oncotype DX test</u>는 주어진 유방암환자에게서 chemotherapy의 효과를 예측할 수 있는 21개의 유전자 test를 한다.
- Biomarker에 따라서 Melanoma와 같은 특정한 암 환자에게 적용되는 test도 있고 많은 cancer type에서 공통되게 발견되는 biomarker들을 test한다.



# First-in-Human Phase 1 Studies in Oncology

- 항암 1상 임상시험은 건강인 보다는 환자를 대상으로 한다는 점에서 여타 의약품 임상시험과 다르다.
- Targeted drug의 임상시험 에서는 환자군이 좀더 정밀하게 정의되며 효율적인 참가 자격이 요구된다. 임상시험의 목표가 MTD (maximum tolerated dose)에서 RPTD (Recommended Phase 2 Dose)로 바뀌었다.
- Biological doses의 定義, 대리변수(surrogate maker) 분석을 위한 fresh tumor tissue 수집, infusion 과정에서 발생할 수 있는 MAB (monoclonal antibodies) 반작용 등을 고려하여 FIH (first-in-human) study를 하는 挑戰이 있다.

항암1상 임상시험은 변화를 요구한다. 변화하는 1상 임상시험의 복잡한 항암 의약품 개발과정이 의료진의 항암연구 교과과정의 중요한 부분이 되어야 한다.







https://www.cancer.gov/about-cancer/treatment/types

https://www.researchgate.net/publication/254285428\_First-in-Human\_Phase\_1\_Studies\_in\_Oncology\_The\_New\_Challenge\_for\_Investigative\_Sites

https://www.annalsofoncology.org/article/S0923-7534(19)45984-X/fulltext



### LSK's Experience in Oncology Trials



Indication	총합계
Acute Lymphoblastic Leukemia	1
Acute Myelogenous Leukemia	4
Bone Metastasis	1
Brain Cancer	4
Breast cancer	23
Cancer	5
Cervical intraepithelial neoplasia III(CIN3)	1
Cervix cancer	1
Childhood cancer	1
Chronic Lymphoblastic Leukemia	1
Chronic Myelogenous Leukemia	4
Colorectal Cancer	11
Diffuse large B-cell lymphoma	1
DLBCL(Diffuse Large B-cell Lymphoma)	1
EBV(+) lymphoma	2
Gastric cancer	13
Glioblastoma	2
Hematologic Malignancy	2
Hepatocellular carcinoma(HCC)	17
Hepatoma	1
Improvement of Fatigue	1
Lung cancer	4
Melanoma	1
Metastasis Colorectal cancer	1

Indication	총합계
Metastatic Breast Cancer(mBC)	1
Multiple Myeloma	6
Myelodysplastic syndrome (MDS)	1
Neutropenia	6
Non-Hodgkin's Lymphoma	1
NSCLC	31
Ovarian cancer	1
Pancreatic Cancer	7
Peripheral T cell Lymphoma	1
Ph+Chronic myelogenous Leukemia	1
Prostate cancer	7
Renal cell carcinoma	7
Sarcoma	1
Solid Cancer	27
Therapeutic Vaccine(HPV)	1
Thymic epithelial tumour(흉선상피종양)	1
TNBC(Triple Negative Breast Cancer)	2
Urothelial Cell Cancer(UCC)/Renal Cell Cancer(RCC)	2
antiemesis drugs	2
UK	4
총합계	213





#### **Oncology Experience** – Oncology Clinical Trial Experience (Early Phase)

Oncology Indication	I	l(FE)	1/11	l/lla	lb	lb/lla	llT(l)	총합계
Acute Myelogenous Leukemia	2							2
Brain Cancer						1		1
Breast cancer	3							3
Cervix cancer			1					1
Childhood cancer	1							1
Colorectal Cancer						1		1
Diffuse large B-cell lymphoma	1							1
EBV(+) lymphoma	1							1
Gastric cancer					1			1
Glioblastoma						1		1
Hematologic Malignancy	1							1
Hepatocellular carcinoma(HCC)						1		1
Metastasis Colorectal cancer	1							1
Multiple Myeloma					1			1
Neutropenia	3							3
NSCLC	4	1	3	1	1			10
Ovarian cancer	1							1
Pancreatic cancer			1	1				2
Prostate cancer	1							1
Solid Cancer	19		2	1	2		1	25
TNBC(Triple Negative Breast Cancer)				1		1		2
UK	1							1
총합계	39	1	7	4	5	5	1	62



#### **Oncology Experience** – PD1/PDL-1/CTLA4 target indications for approved drugs

Year	Product type	Indication	Study Phase	No. of Subjects	No. of sites	Service scope	Study Global/Local
2021	anti-PD-L1 Ab(Durvalumab) Combination trial	Urothelial Cell Cancer(UCC)/ Renal Cell Cancer(RCC)	11	48	2 (USA)	Data Management	Global Project
2019	anti-PD-L1 IgG1 type monoclonal antibody	cancer	IIT(II)	50	1 (Korea)	Pharmacovigilance	Local Project
2018	anti-PD-1 Ab (Pembrolizumab) Combination Trial	TNBC(Triple Negative Breast Cancer)	lb/lla	83	12 (Korea)	Clinical Operation Data Management Statistics Medical Writing Project Management	Local Project
2014	anti-PD-1 Ab (Nivolumab) Combination Trial	NSCLC	I	18	5 (Korea)	IND Submission Clinical Operation Data Management Statistics Medical Writing (CSR) Project Management	Global Sponsor
2014	anti-PD-1 Ab (Nivolumab) Combination Trial	NSCLC	II	104	10 (Korea)	IND Submission Clinical Operation Data Management Statistics Medical Writing Project Management	Global Sponsor



#### FIH Case Study – Australia and South Korea Enrollment and Timeline

Protocol Title	XXXX phase 1 FIH study for ac	lvanced cancer patients			
Number of Patients	Part A 40, part B 60 (30 advance	ed/metastatic gastic cancer patient	s, 30 NSCLC patier	nts)	
Desim	Part A : Maximum tolerance dos times/day	e estimation (multi-centre, open, d	ose escalation stud	y), PK, PD, adminis	tered 1 or 2
Design	Part B : Extension study based o gastric cancer or advanced NSC	on suggested dose from Part A, ide CLC.	entifying PK variable	es and/or PD bioma	rker from advanced
IND Submission		2010-10-18 (Initial su	ıbmission)		
Sites	Enrollment/Dosed Status: Part A*	Enrollment/Dosed Status: Part B	IRB Submission Date	IRB Approval Date	SIV Date
Center 1(South Korea	5	19	2010-11-17	2010-12-13	2011-03-07
Center 2(South Korea)	5	21	2010-11-11	2010-12-03	2011-02-11
Center 3(South Korea)	6	11	2010-11-08	2010-11-24	2011-02-14
Center 4(Australia)	8	3	UK	UK	2010-12-02
Center 5(Australia)	12	4	UK	UK	2010-11-22



## A Global Gastric Cancer Experience

Global Project Management by LSK Global PS as Lead CRO (2016~2019.05 DBL)

al Project Example Category	Content	Total 1		trioc OF ci	toc
Therapeutic area	Oncology	TOLAL		tries, 95 si	les
Study type	Double-blind Ph3 Clinical Trial				
Locations	Total 12 Countries, 95 Sites				See and
Number of Cubicot				0 - 0	
Number of Subject	460		35		
Status	460 Recruitment Completed	USA 1			
		USA 1	Eur	ope 8	Asia-Pacific 3
	Recruitment Completed	USA 1	Euro France	ope 8 Germany	Asia-Pacific 3 Korea
Status	Recruitment Completed Regional CROs : Japan, Taiwan, EU/US	USA 1			
	Recruitment Completed Regional CROs : Japan, Taiwan, EU/US	USA 1	France	Germany	Korea



	LSKG , Korea	Global CRO, EU & US	Local CRO, Japan	Local CRO, Taiwan
# of Sites	22	50	15	8
Site Feasibility Completion	13-Sep-16	30-Oct-16	15-Dec-16	13-Sep-16
Regulatory Submissions	07-Dec-16	Dec 2016 – May 2017	07-Dec-16	16-Dec-16
Regulatory Approvals	06-Jan-17	US : 26-May-2017 EU Region : 10-Apr-18 (last)	06-Jan-17	16-Feb-17
Site Initiation Visit	24-Feb-17	US: 04 May 2017 EU Region : 13 Oct 2017 (first)	28-Mar-17	05-May-17
First Patient Screening	08-Mar-17	US : 01-Sep-17 EU Region : 11-Dec-17	05-Apr-17	03-Aug-17
First Patient In	14-Mar-17	US : 02-Jan-18 EU Region : 19-Dec-17	13-Apr-17	23-Aug-17
Subjects Enrolled	214	150	59	37
CRO Cost	\$9.5M*	\$10.4M	\$4.6M	\$0.6M
Per patient CRO Cost	\$44,381*	\$69,005	\$77,527	\$17,307

\*: Including DM/STAT/Global PM/Global PV/MW etc. If limited to just patient management and RA support, the cost could have been lowered by 1/3 to \$30,000.



### Symposium 일정



9:30	9:45	0:15	Opening	<b>이영작 대표</b> LSK Global PS
9:45	10:35	0:50	항암제 1상 임상시험 설계 전반	안철우 교수 UT Southwestern Medical Center
10:35	11:00	0:25	Q&A / 휴식	
11:00	11:50	0:50	Bayesian Optimal Interval (BOIN) Design	<mark>길시연 팀장</mark> LSK Global PS
11:50	12:10	0:20	Q&A / 휴식	
12:10	13:00	0:50	Model-based, Model-assisted Designs for Early Phase Clinical Study: CRM, mTPI, Keyboard Design etc.	<b>이정복 교수</b> 서울아산병원
13:00	14:00	1:00	점심식사	
14:00	14:30	0:30	항암제 초기 임상에서 Effective Dose 결정 시 고려 사항	<b>나현희 상무</b> LSK Global PS
14:30	14:50	0:20	Q&A / 휴식	
14:50	15:40	0:50	PV in Phase I Oncology Study	<b>이정민 상무</b> LSK Global PS
15:40	16:00	0:20	Q&A / 휴식	
16:00	16:50	0:50	항암제 1상 통계분석 사례	<b>박병관 상무</b> LSK Global PS
16:50	17:00	0:10	Q&A	





# 감사합니다.



2021-06-04